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Abstract 
The distribution and depletion profile of sulfadiazine (SDZ) were investigated in gilthead sea bream (Sparus aurata) fed on fish 
oil (FO) or plant oil-based (PO) diets. Fish averaging 230 g were given medicated feed containing 25 mg SDZ kg-1 fish for 5 days at 
24-26oC. Blood and muscle plus skin were sampled on days 1, 3, 5, 6, 8 and 9.  Differences in plasma and fillet SDZ levels between 
the two groups were statistically insignificant. The maximum drug concentrations in plasma were 3.2 ± 1.9 μg mL-1 and 2.9 ± 1.2 μg 
mL-1 in the PO and FO groups, respectively. In post-medicated samples depletion rapidly reached concentrations close to the level of 
quantification at 72 h post medication. Withdrawal times to reach consumer safety levels were calculated to be 103 and 118 h for the 
FO and the PO groups, respectively. N4-acetylation was found to be the major metabolic pathway of SDZ in gilthead sea bream fillet 
accounting for 23 and 19% of the parent compound in the FO and the PO groups, respectively. Overall, alteration of the dietary lipid 
profile induced insignificant effects on the kinetics of SDZ. The high tissue SDZ levels during medication and the fast removal of the 
parent compound and its metabolites from edible tissues of gilthead sea bream reflect a promising antibacterial profile. 
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Introduction
Sulfonamides such as sulfadiazine (SDZ), sulfam-
ethoxazole (SMX) and sulfadimethoxine (SDM), play 
an important role as effective chemotherapeutics of bac-
terial pathogens in veterinary medicine (EMEA, 1995). 
Sulfonamides are commonly combined with pyrimidine 
potentiators due to the beneficial effect of the combined 
efficacy, which is greater than the potencies of either 
drug individually. The recommended dosage of potenti-
ated sulfonamides against bacterial fish pathogens is 25 
mg sulfonamide and 5 mg kg-1 fish of the pyrimidine po-
tentiator for 5–10 d (Scott, 1993). 
There is sufficient data on the kinetics of sulfona-
mides after oral administration in farmed fish such as 
Atlantic salmon (Salmo salar) (�ormazabal � �ogs-
tad, 1992; Samuelsen et al., 1995, 1997; �orsberg et 
al., 1997), chinook salmon (Oncorhynchus tshawytscha) 
(Zheng et al., 1994), channel catfish (Ictalurus puncta-
tus) (Michel et al., 1990; Du et al., 1995), rainbow trout 
(Oncorhynchus mykiss) (Salte � Liestol, 1983) and At-
lantic cod (Gadus morhua) (Samuelsen, 2006). 
Limited information is however available on the 
kinetic profile of sulfonamides in Mediterranean finfish 
species. Sulfonamides are commonly used in combi-
nation with pyrimidine potentiators at a dose of 30 mg 
kg-1 for 5 d against a wide range of bacterial pathogens 
affecting gilthead sea bream (Sparus aurata); the most 
commercialized Mediterranean farmed fish species. The 
most important pathogenic bacteria include Vibrio algi-
nolyticus, V. ordali, Listonella (Vibrio) anguillarum and 
Photobacterium damselae ssp. piscicida (Zorrilla et al., 
2003). In particular, some information with respect to 
the removal of SDZ and SDM from the edible tissues of 
gilthead sea bream has been provided (Papapanagiotou 
et al., 2002; �omero Gonzalez et al., 2010), although 
withdrawal times (WT) were not calculated. Moreover, 
therapeutic circulatory levels of sulfonamides during the 
dosing intervals are lacking in euryhaline fish species. 
Consequently, the first aim of this study was thor-
ough investigation of the blood and fillet distribution of 
SDZ, during and following medication, in gilthead sea 
bream. The edible portion was also screened for meta-
bolic products of SDZ. The second goal was to evaluate 
whether shifts in the dietary lipid source, a strategy sus-
taining the need for fish meal and oil replacement with 
sustainable sources (�ardy, 2008), may have an impact 
on SDZ tissue concentration and depletion profile. In this 
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study, fish oil was partially replaced with oils of plant 
origin such as rapeseed, linseed and palm oil. These al-
ternative oil sources do not compete with the human food 
grade industry (Tacon � Forster, 2001) and furthermore 
induce minor adverse effects on the overall performance 
of fish (Fountoulaki et al., 2009).
Materials and Methods
Chemicals
Sulfadiazine and metabolites of high purity (> 99%) 
were obtained from Sigma (USA). �igh-performance 
liquid chromatography (�PLC) grade solvents were ob-
tained from Labscan (Ireland). The Isolute C18 columns 
used for solid phase extraction (SPE) were purchased 
from International Technology (Sorben, UK). Commer-
cial grade potentiated sulfonamide (50% powder) con-
taining SDZ and trimethoprim as a pyrimidine compound 
was obtained from Vethellas SA (Greece). 2-phenox-
yethanol was purchased from Pharmaqua (Greece). Ana-
lytical grade chemicals obtained from Labscan (Ireland) 
were used for tissue analysis. 
Fish and Experimental Design
Five hundred gilthead sea bream (230 ± 45 g) were 
obtained from Selonda Aquaculture SA (Greece) and ac-
climated to the experimental diets for 3 months prior to 
initiation of the experiments. For each treated group (PO 
and FO), fish were equally divided into 1 m3 triplicate net 
cages located within a 18 m3 cement tank and supplied 
with marine water of 38 g L-1 salinity. Experiments were 
carried out in water temperatures (24-26oC) common 
during bacterial outbreaks.
Experimental diets
The composition of experimental diets is given in 
Table 1. Along with the inclusion of plant meals substi-
tuting almost 50% of the fish meal in both experimental 
diets, 66% of fish oil (10% of the diet) was replaced by 
rapeseed, linseed and palm oils in PO diet. Fish were fed 
with the diet for three months before commencement of 
therapy. Medicated diets were prepared from the com-
mercially prepared diet after milling, mixing with the 
drug and re-pelleting at low temperature. They were de-
livered by hand once a day at a rate of 2 % b.w. at 13:00 
during therapeutic days. The dosing regimen aimed for 
25 mg kg-1 fish for 5 days, representing the recommend-
ed treatment schedule for potentiated sulfonamides. The 
concentration of SDZ in the diets was checked before ad-
ministration of the medication. 
Fatty acids analysis of feeds 
Lipids from feeds were extracted using a chloro-
form: methanol (2:1 v:v) mixture, according to Folch et 
al. (1957). The fatty acid methyl esters were prepared 
by transesterification with anhydrous methanol contain-
ing 2% sulphuric acid, for 16 h at 500oC under nitrogen 
(Christie, 1989) and separated, identified and quantified 
by gas liquid chromatography under the conditions previ-
ously described by Fountoulaki et al. (2003). Fatty acid 
methyl esters were identified by comparison to an exter-
nal standard (Supelco TM 37 component FAME Mix).
Sampling
Fish were anesthetized with 2-phenoxyethanol (2 
mL L-1) before handling. Nine fish from triplicate cages 
were sampled at 10:00 on days 1, 3 and 5 (last day of 
Table 1. Composition of experimental diets (%).
Ingredient (%) Fish oil–based diets Plant oil-based diets
Fish meal (Crude protein 70 %) 15 15
Fish protein concentrate (CPSP 902) 5 5
Corn gluten 40 40
Soybeam meal 14 14
Extruded wheat 4 4
Fish oil 15 5
Rapeseed oil 0 1.7
Linseed oil 0 5.8
Palm oil 0 2.5
Soya lecithin 1 1
Binder 1 1
Mineral premix 1 1
Vitamin premix 1 1
CaHPO4.2H20 (18 %P) 2 2
L-Lysine 0.55 0.55
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medication) and 6, 8 and 9 (post-medication); blood (1 
mL) and muscle plus skin samples were collected. Day 1 
was set at 24 h post 1st day of medication. Muscle plus 
skin samples were prepared by grounding approximately 
30 g fillets. �eparin treated plasma was processed from 
blood samples by centrifugation at 5000 rpm. All samples 
were stored at -80oC until analysis.
Analysis of SDZ and metabolites 
The analysis of SDZ and its metabolites (N4-acetyl 
SDZ) was simultaneous and based on a recently devel-
oped LC/MS method. For SDZ analysis in fillets, a solid 
phase dispersion method was applied. Briefly, 0.5 g of 
fillet was carefully grated with 1 g C18 material in a glass 
mortar using a pestle to obtain a well dispersed and free 
flowing mass. Subsequently, this was loaded in a syringe, 
and compressed by a plunger. The mixture was placed to 
SPE equipped with empty C18 columns (6 mL) and SDZ 
was slowly extracted by 14 mL dichloromethane. After 
evaporation of the solvent, the extract was reconstituted 
in mobile phase (water/methanol: 90/10 with formic acid 
0.05 %). The solution was washed with 1 mL n-heptane 
and centrifuged at 5000 rpm. Then, the heptane layer was 
rejected (upper layer) and the water methanol layer was 
injected into the �PLC column after filtration (0.22 μm). 
The detection was based on LC/MS with Electro Spray 
Ionization (API-ES), with positive ion detection (2695 
Alliance pump, Waters, coupled to a ZQ 2000 single 
quadrupole mass spectrometer, Micromass, Manchester, 
UK). The column used was an X-Terra C18 column 2.1 
x 100 mm, 3.5 mm. The flow rate of the mobile phase 
was kept at 0.2 mL min-1, temperature at 40oC and a gra-
dient of water/methanol containing 0.05 % formic acid 
was applied, starting for a more aqueous mobile 90/10 
water/methanol, to remove water soluble contaminants, 
and then increasing to 80 % methanol. The column was 
then equilibrated back to the initial conditions. The MS 
conditions included the positive SIM ion 251 m/z for 
SDZ and 293 m/z for N4-acetyl SDZ metabolite. The re-
covery of the method averaged 87% and 93% for SDZ 
and N4-acetyl SDZ, respectively using spiked samples 
at 0.05, 0.1, 0.15 mg kg-1 tissue. The limit of detection 
(LOD) was 0.005 mg kg-1, while the limit of quantifica-
tion (LOQ) based on a signal to noise ratio of 10 was 
0.015 mg kg for analysis in plasma samples, 200 μL of 
plasma was vortexed with 2 mL ethyl acetate and 300 
mg Na2SO4 and centrifuged at 2,600 rpm for 8 min. The 
supernatant was evaporated and the extract was reconsti-
tuted in the mobile phase described above. The solution 
was vortexed with n-heptane and centrifuged at 3,000 
rpm for 10 min. The upper layer was discarded and the 
water methanol layer was injected into the �PLC column 
after filtration (0.22 μm). The chromatological conditions 
and equipment were identical to the procedure described 
for SDZ and N4SDZ analysis in fillet. The recovery of 
the method averaged 92% and was tested using spiked 
samples at 0.1, 0.25, 0.5, and 1 mL-1 plasma. The LOD 
and LOQ were 0.002 and 0.010 μg mL-1, respectively. 
Feed samples were analyzed for SDZ content in a similar 
manner described for drug analysis in plasma samples.
Withdrawal Time Calculation
WT of SDZ from muscle plus skin was measured 
using the WT 1.1 program (withdrawal-time calcula-
tion program, P. �ekman, Agency for the registration of 
veterinary medicinal products, B�D, The Netherlands). 
Calculation of WT was based on the sum of SDZ and 
its metabolite levels measured on days 5, 6, 8 and 9. A 
confidence limit was set at 99 %.
Statistical Analysis
Data were checked for homogeneity of variances 
(Levene) and normality (Kolmogorov–Smirnov) prior to 
statistical analysis. Concentrations of SDZ in analyzed 
plasma and muscle plus skin tissues at each sampling 
point from the two experimental groups were compared 
by student’s t-test (P < 0.05).
Results
Analysis of the medicated diet demonstrated that the 
feed contained 97% of the originally introduced drug 
concentration. The lipid profile of the experimental diets 
is given in Table 2. The most obvious differences in the 
fatty acid profile between PO and FO diets were related 
to the amount of ω6, which was found in a higher level 
in the PO group mainly due to the 18:2ω6 (linoleic acid) 
concentration. On the contrary, the FO group displayed 
higher levels of docosahexaenoic acid (D�A) and eicos-
apentaenoic acid (EPA).
Fish appetite was high during treatment and the entire 
medicated diet was rapidly consumed by the treated fish. 
Differences in plasma (Table 3) and fillet SDZ levels (Ta-
ble 4) between the PO and FO groups were statistically 
insignificant. The maximum SDZ plasma concentrations 
were measured to be 3.2 ± 1.9 μg mL-1 on day 2 and 2.9 
± 1.2 μg m-1 on day 1 in PO and FO groups, respectively. 
Accordingly, the highest SDZ levels in muscle plus skin 
were found to be 2.6 ± 1.3 mg kg-1 in the PO and 1.7 ± 
0.3 mg kg-1 in the FO group, both on day 1. The drug was 
rapidly removed from gilthead sea bream circulation af-
ter completion of the treatment. Similarly, elimination of 
SDZ from fish fillet reached levels below to the LOQ 4 d 
after the last dosage very fast. N4-acetylation was found 
to be the major metabolic pathway of SDZ in gilthead 
sea bream fillet. N4-acetyl metabolites accounted for 23 
and 19% of the parent compound measured in the FO and 
PO groups, respectively during medication (Table 4), and 
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were rapidly removed when treatment ceased. The WTs 
from edible tissues to reach consumer safe levels were 
calculated to be 103 and 118 h for the FO and PO groups.
Discussion
This is the first study investigating the kinetic be-
haviour of SDZ in gilthead sea bream as well as the ef-
fects of dietary oil background on the drug kinetics. The 
analysis of the dietary fatty acid profile reflected the vari-
ation of the oil sources used in the feeds (Fountoulaki et 
al., 2009). �igher concentrations of ω6 fatty acids and 
D�A+EPA were measured in the PO and FO groups, re-
spectively. Importantly, dietary lipids may influence the 
tissue fatty acid profile and possibly the composition of 
membrane phospholipids that determines physical prop-
erties such as fluidity and permeability, which in turn 
may interfere with drug absorption (Lin � Lu, 1997). 
Indeed, the fatty acid profile of gut and liver of gilthead 
sea bream fed with identical diets (�igos et al., 2011) fol-
lowed the dietary lipid pattern found here. Moreover, the 
relationship between dietary lipids and P4501A content 
and activity, a hepatic enzyme highly involved in the me-
tabolism of drugs, has been demonstrated (Ammouche 
et al., 1993). This study failed, however, to demonstrate 
that dietary oil manipulations may significantly influence 
the kinetics of SDZ in gilthead sea bream. Nevertheless, 
fish oil replacement with rapeseed, linseed and palm oil 
resulted in insignificant differences in tissue SDZ levels 
among fish fed on the PO diet versus those fed an FO 
diet. Similarly, no pharmacokinetic differences were ob-
served between fish fed on conventional or plant-based 
diets when oxytetracycline was delivered in gilthead sea 
bream (�igos et al., 2011) and oxolinic acid in Atlantic 
salmon (Lunestad et al., 2010).
Levels of SDZ in muscle plus skin of gilthead sea 
bream were highest at the beginning of therapy, but then 
decreased rapidly even during the medication period. An 
accumulative drug profile instead of a fluctuating or a de-
creasing pattern is usually expected during the medica-
tion period. This is the case when the pharmacokinetic 
parameters of the drug hypothetically remain constant 
with distribution rate being higher than elimination dur-
Table 3. SDZ levels (μg mL-1) in plasma of sea bream fed FO 
and PO at high water temperatures during (days 1, 3, 5) and 
after SDZ treatment (days 6, 8, 9). Each data point represents 
the mean ± s.d, n=9. 
Days FO-SDZ PO-SDZ
1 2.938 ± 1.181 3.134 ± 0.989
3 2.367 ± 1.441 3.223 ± 1.897
5 1.594 ± 0.682 1.322 ± 0.547
6 0.036 ± 0.021 0.034 ± 0.015
8 0.017 ± 0.038 0.013 ± 0.009
9 0 0
Table 2. Fatty acid profile of FΟ and PO diets.
Fatty acids FO PO
14:0 5,08 3,46
15:0 0,44 0,3
16:0 15,27 15,48
17:0 0,41
18:0 (steatic acid) 2,15 2,48
16:1ω9 0,21 0,17
16:1ω7 4,53 3,03
17:1ω9 0,37
18:1ω7 2,52 2
18:1ω9 (oleic acid) 15,27 21,84
20:1ω7 0,26 0,16
20:1ω9 7,44 5,01
22:1ω7 0,23
22:1ω9 1,42 0,71
22:1ω11 10,32 6,38
24:1ω9 1,17 0,72
16:1ω9 0,21 0,17
16:2ω4 0,34 0,23
16:3ω3 0,23
16:4ω3 0,4 0,39
18:2ω9 0,49 0,32
18:2ω6 (linoleic acid) 5,27 15,5
18:3ω3 (a-linolenic acid) 3,11 7,96
18:4ω3 2,08 1,3
20:2ω9 0,27 0,2
16:2ω4 0,34 0,23
16:3ω3 0,23
20:4ω3 0,5 0,32
20:4ω6 (arachidonic acid) 0,53 0,3
20:5ω3 (EPA) 7,47 4,62
22:4ω6 0,24
22:5ω3 0,95 0,6
22:6ω3 (DHA) 10,96 6,32
∑PUFA 32,84 38,06
∑MUFA 43,74 40,02
∑ω9 26,64 28,97
∑ω3 25,7 21,51
∑ω6 6,04 15,8
EPA+DHA 18,43 10,94
n3/n6 4,25 1,36
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ing the entire course of the therapy. A fluctuation of SDM 
levels during treatment associated with a similar distribu-
tion profile were also apparent in edible tissues of gilt-
head sea bream that received 50 mg g-1 fish for 5 d at 
26oC (Papapanagiotou et al., 2002). In particular, while 
the maximum drug concentration was measured on day 
1 (1.39 mg kg-1), tissue levels then followed a decreasing 
fluctuating pattern ending at a level of 0.71 mg kg-1 on 
day 5. Similar findings have also been observed in gilt-
head sea bream medicated with oxolinic acid and oxytet-
racycline (�igos et al., 2003; 2011). The lack of accumu-
lative drug profile with respect to disease treatment may 
require changes of the treatment schedule such as higher 
dosages or multiple medicated feedings on a daily basis. 
Sulfonamides are included in Annex I of Council 
�egulation (EEC) No 2377/90 and the maximum residue 
level (M�L) of the sum of sulfonamides in edible portions 
of farmed animals has been set at 0.1 mg kg-1 (EMEA, 
1995). �emoval of SDZ from gilthead sea bream fillet was 
fast when treatment ceased, reaching levels close to the 
LOQ, 4 d after the last dose. WT were calculated to be 103 
and 118 h for the FO and PO groups, respectively. Simi-
larly, depletion of SDM delivered in combination 5:1 with 
ormetoprim at 50 mg kg-1 fish for 5 d, was rapid in gilthead 
sea bream kept at 26oC (Papapanagiotou et al., 2002). In 
this study, drug levels dropped below of LOQ (33.3 μg kg-
1), 24 h following treatment (Papapanagiotou et al., 2002). 
�omero Gonzalez et al. (2010) reported that in gilthead 
sea bream maintained at either 14 or 19.5oC, no detect-
able SDZ (given at 30 mg kg-1 fish for 10 d) concentrations 
were measured in edible tissues 35 d after treatment. This 
represents a much longer withdrawal period compared to 
the two aforementioned studies and possibly indicates the 
effect of the lower temperatures used. 
Depletion of sulfonamides has been found to be 
slower in cold water farmed fish, but fairly rapid in fresh 
warm water fish species. For example, Salte � Liestøl 
(1983) recommended a SDZ WT approaching 60 d at 
>10oC and 100 days at 7-10oC in rainbow trout muscle 
dosed with 15-30 mg for 10 d. A 12-day WT period was 
suggested for Atlantic salmon muscle given 25 mg SDM 
kg-1 fish for 5 d at 10oC. On the contrary, rapid depletion 
of SDM was evident in channel catfish muscle medicated 
with 42-100 mg kg-1 fish for 5 d at 27-28oC, where no 
residues above the legal tolerance (US Food and Drug 
Administration: 0.1 mg kg-1) were measured 2 days post-
treatment (Du et al., 1995; Walker et al., 1995).
Metabolism of sulfonamides under N4-acetylation, 
hydroxylation and glucuronidation occurs in animals in-
cluding fish (Grondel et al., 1986; Squibb et al., 1988; 
Ishida, 1989; van Ginneken et al., 1991; Kleinow et al., 
1992; Nouws et al., 1993; Uno et al., 1993; Zheng et al., 
1994; Samuelsen et al., 1995, 1997; Samuelsen, 2006). 
N4-acetylation has been reported as the major metabolic 
route in fish (Squibb et al., 1988; Uno et al., 1993; Samu-
elsen et al., 1995). Water temperature appeared to affect 
the metabolic processes of sulfonamides in fish. Specifi-
cally, a significant increase in acetylation and a decrease 
in hydroxylation of SDM were observed in common carp 
plasma with increasing temperature (Nouws et al., 1993). 
Interestingly, the N4-acetyl metabolite of sulfonamides 
may stay longer than the parent compounds in the tis-
sues of treated fish with the possibility to convert back 
to the parent drug via a deacetylation process (Uno et al., 
1993). It is still unknown whether the processes of sul-
fonamide acetylation and deacetylation are related to the 
same or different enzymatic systems. WT calculations 
from edible tissues should therefore consider the above 
reactions, including both the added quantity of metabolic 
products of sulfonamides and the possible prolonged 
presence of particular metabolites in the animal. 
N4-acetylation was the major metabolic pathway of 
SDZ in gilthead sea bream fillet during medication, av-
eraging 23 and 19% of the parent compound for the FO 
Table 4. SDZ and its N4-acetyl metabolite levels (mg kg-1) in muscle plus skin of sea bream fed FΟ and PO diets at high water 
temperatures during (days 1, 3, 5) and after SDZ treatment (days 6, 8, 9). Each data point represents the mean ± s.d, n=9. �atios 
are calculated from the concentration means of the parent compound and its metabolite during treatment.
Days FO-SDZ PO-SDZ FO- N4SDZ PO- N4SDZ FO-SDZ/ FO- h (%)
PO-SDZ/ 
PO- N4SDZ
(%)
1 1.728 ± 0.293 2.611 ± 1.257 0.328 ± 0.115 0.279 ± 0.102 19 11
3 0.417 ± 0.192 0.624 ± 0.265 0.110 ± 0.064 0.163 ± 0.102 26 26
5 0.607 ± 0.202 0.748 ± 0.304 0.129 ± 0.063 0.162 ± 0.064 23 22
6 0.036 ± 0.022 0.035 ± 0.015 0.006 ± 0.004 0.005 ± 0.003
8 0.018 ± 0.005 0.013 ± 0.009 0 0
9 0 0 0 0
Averaged ratio 23 19
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and PO groups, respectively. As opposed to the findings 
of Uno et al. (1993), depletion of the N4-acetyl metabo-
lite in gilthead sea bream was even faster than the parent 
substance, reaching levels below LOQ 24 h after treat-
ment termination in both groups. In other species such as 
Atlantic cod, N4-acetylation of SDM was considered to 
be a metabolic pathway with moderate importance while 
edible tissues were not sampled (Samuelsen, 2006). N4-
acetylation however appeared to be a major part of SDM 
metabolism in Atlantic salmon (Samuelsen et al., 1995; 
1997), channel catfish (Squibb et al., 1988) and rainbow 
trout (Uno et al., 1993). For example, the sulfonamide 
derivatives accounted for 29-37% of the parent com-
pounds in fish muscle at 24 h post-dosing in the most 
recent study by Uno et al. (1993). 
Similar to what was found in the distribution profile 
in muscle plus skin, SDZ lacked an accumulative incre-
ment in gilthead sea bream plasma even after multiple 
dosing. Plasma concentrations of SDZ in gilthead sea 
bream ranged from 1.6 ± 0.7 to 2.9 ± 1.2 μg mL-1 and 
from 1.3 ± 0.5 to 3.2 ± 1.9 μg mL-1 in fish fed on the 
FO and PO based diets, respectively, during the thera-
peutic period. Considering the experimental differences 
between various studies, the above values are lower com-
pared to the maximum SDM plasma concentrations in 
Atlantic salmon (10-14 μg mL-1) given 25 mg kg-1 fish by 
either single or multiple dosing (Samuelsen et al. 1995, 
2007), in Atlantic cod (20.9 μg mL-1) forced-medicated 
with 25 mg kg-1 fish (Samuelsen, 2006), in channel catfish 
(9.1 μg mL-1) delivered 42 mg kg-1 fish for 5 d (Walker et 
al., 1995) and rainbow trout serum (36.1 μg mL-1) after 
administration of 200 mg kg-1 fish via a catheter (Uno et 
al., 1993). The differences in gastric emptying rates be-
tween gilthead sea bream and other farmed species could 
explain the variation in tissue SDZ concentrations. SDZ 
was rapidly removed from gilthead sea bream circulation 
when treatment ceased, possibly indicating the need for 
more prolonged treatment schedules in cases of persist-
ing bacterial infections. Sulfonamide metabolites have 
been detected not only in tissues but also in the circula-
tion system of many fish species (Grondel et al., 1986; 
van Ginneken et al., 1991; Uno et al., 1993; Samuelsen 
et al., 1995; 1997); however, no SDZ derivatives were 
detected in gilthead sea bream plasma. 
In attempting to simulate the environmental condi-
tions where natural bacterial infections most commonly 
emerged in farmed gilthead sea bream, experiments were 
carried out at high water temperatures in this study. The 
direct effects of water temperature on the kinetics of an-
tibacterials have been widely demonstrated (�igos � Tr-
oisi, 2005). Lower water temperatures reduce the meta-
bolic rate of fish (Ellis et al., 1978) and inevitably the 
distribution and depletion rate, which in turn can result 
in higher tissue concentrations during therapy and slower 
withdrawal. Given the above assumptions, the adjustabil-
ity of recommended treatment schedules based on altered 
environmental conditions is of primary importance for 
safe and effective therapy.
Minimum inhibitory concentration (MIC) of SDZ or 
potentiated sulfonamides concerning bacterial pathogens 
of Mediterranean farmed fish species are very limited 
(Lagana et al., 2011). There is therefore inadequate bib-
liographic information to implement MIC data of SDZ 
with circulatory SDZ levels in gilthead sea bream and 
thus to select the best correlation with bacteriological and 
clinical outcomes. 
In conclusion, shifts in the dietary lipid sources, re-
sulting from replacement of fish oil with rapeseed, lin-
seed and palm oil, induced insignificant effects on the 
kinetics of the SDZ in gilthead sea bream. �emoval of 
SDZ and its N4-acetyl metabolites from fish fillet after 
treatment was rapid with withdrawal times calculated to 
be below 118 h at summer temperatures. The high tissue 
SDZ levels during medication and the fast withdrawal 
from edible tissues of gilthead sea bream reflect an at-
tractive antibacterial profile.
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